Who Owns Galectin Therapeutics Stock?
NASDAQ: GALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 15.66%
- Held by insiders
- 53.08%
- Institutional holders
- 133
- Institutions 15.7%
- Insiders 53.1%
- Public and other 31.3%
Who owns Galectin Therapeutics stock?
Institutional investors own about 15.7% of Galectin Therapeutics's shares, spread across 133 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 53.08% of GALT.
The largest institutional holders are Blackrock Inc. (2.96%), Vanguard Capital Management LLC (2.15%) and Geode Capital Management, LLC (1.30%). Together, the top 10 institutions control 10.8% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their GALT positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of GALT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 2.99M | 2.96% | +273.9% |
| Vanguard Capital Management LLC | 2.17M | 2.15% | +10.3% |
| Geode Capital Management, LLC | 1.31M | 1.30% | +113.5% |
| Osaic Holdings Inc. | 1.20M | 1.19% | +7.2% |
| Marshall Wace LLP | 831.01K | 0.82% | -31.9% |
| Wealthspire Advisors, LLC | 721.79K | 0.72% | 0.0% |
| State Street Corporation | 567.78K | 0.56% | +119.7% |
| Commonwealth Equity Services, LLC | 407.11K | 0.40% | +10.9% |
| Northern Trust Corporation | 386.55K | 0.38% | +196.3% |
| Vanguard Fiduciary Trust Co | 366.48K | 0.36% | +20.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of GALT
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.52M | 1.51% |
| iShares Trust-iShares Russell 2000 ETF | 1.05M | 1.04% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 594.71K | 0.59% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 520.37K | 0.52% |
| iShares Trust-iShares Russell 2000 Growth ETF | 312.25K | 0.31% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 265.47K | 0.26% |
| iShares Trust-iShares Micro-Cap ETF | 164.30K | 0.16% |
| iShares Trust-iShares Russell 2000 Value ETF | 154.44K | 0.15% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 116.40K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 95.41K | 0.09% |
Frequently asked questions
Who is the largest shareholder of Galectin Therapeutics?
Blackrock Inc. is the largest institutional shareholder of GALT, owning 2.96% of shares outstanding (2.99M shares) as of its latest 13F filing.
What percentage of Galectin Therapeutics is owned by institutions?
Institutions own about 15.7% of GALT shares and 33.4% of the public float.
How much of Galectin Therapeutics do insiders own?
Insiders, such as officers and directors, own about 53.08% of GALT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.